Salvia Bioelectronics BV raised $60 million in a series B financing round for its minimally invasive implantable neuromodulation device, Mysalvia therapy, which treats chronic migraine. The funds will ...

A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments.

GC Genome Corp. priced a Kosdaq offering of 4 million shares at ₩10,500 per share May 27, entailing a gross ₩42 billion (US$30.5 million) raise in early June. The Yongin, South Korea-based genomics ...

Researchers at the University of Michigan designed an optimized viral protein able to boost the antitumor function of T cells. The project stemmed from observations on the particular system employed ...

Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Copyright ©2025. All Rights Reserved.

Individuals with both sickle cell disease (SCD) and sickle cell trait are at higher risk than others of developing renal medullary cancer (RMC), the rarest and deadliest subtype of kidney cancer.

Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease of the central nervous system caused by lytic infection of oligodendrocytes by pathogenic strains of the JC ...

Latus Bio Inc. is developing a new gene therapy, LTS-101, for the treatment of neuronal ceroid lipofuscinosis type2 (CLN2), a form of Batten disease characterized by deficiency in the tripeptidyl ...

Enanta Pharmaceuticals Inc. has described 17β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17β-HSD13) inhibitors reported to be useful for the treatment of liver (hepatocellular carcinoma) cancer, ...

Autobahn Therapeutics Inc. has disclosed fatty acid amide (FAAH) cleavable prodrugs acting as sphingosine 1-phosphate S1P1 receptor (S1PR1; EDG1) and/or S1P5 receptor (S1PR5; EDG8) agonists reported ...

Researchers have been exploring ways to activate the cGAS/STING pathway in tumors as a way to slow their growth.

Aquinnah Pharmaceuticals Inc. has identified microtubule-associated protein tau (PHF-tau; MAPT) aggregation inhibitors reported to be useful for the treatment of Alzheimer's disease and frontotemporal ...